



GET READY FOR THE BEST WEEK EVER

Double rewards on *Dysport*
November 10-15.

Redeem your patients' ASPIRE Galderma Rewards points on a qualifying *Dysport* treatment between November 10-15 and they'll receive DOUBLE the reward value at checkout.*



ASPIRE
GALDERMA PRACTICE REWARDS

Uniquely You. Definitely *Dysport*.



Actual patient.
Individual results may vary.

Dysport® (abobotulinumtoxinA) is a prescription injection for temporary improvement in the look of moderate to severe frown lines between the eyebrows (glabellar lines) in adults less than 65 years of age.

Please read full Important Safety Information, including Distant Spread of Toxin Effect Boxed Warning, on last page.

*Terms and conditions apply.

The Beauty of Self-Expression

Dysport is a fast-acting, long-lasting, and clinically proven treatment for those who want a natural-looking way to smooth frown lines between the brows. *Dysport* matches how patients feel with how they want the world to see them—confident and expressive.^{1-6*}

95%
of users

95% of users were satisfied with only 2 *Dysport* treatments per year.^{6†}

97%
of users

97% of users said their results looked natural.^{6†}

1
day

Users may see results as early as 1 day after treatment.^{2-4†}

5
months

Improvements to frown lines can last up to 5 months.^{2-5*}

Frequently Asked Questions

General

- How does the *Double Rewards* promotion work? For one week only (November 10-15, 2025), eligible patients will earn double rewards when they:

1. Receive a *Dysport* treatment, and
2. Redeem their ASPIRE points toward the same treatment

For example, 200 ASPIRE points are normally worth \$20 off. During the promotion, 200 ASPIRE points are worth \$40 off.

- How do I make sure my patients are getting their double rewards from this promotion? Will I need to adjust pricing or discount at checkout? Aside from filling your appointment books, there are no extra steps that you need to take for patients to receive their rewards. Eligible patients will automatically receive their double rewards once their ASPIRE points have been redeemed and the treatment has been entered—no additional discounting required.
- How will my patients know that this promotion is happening? ASPIRE will deploy robust communications via email, app, and social media. You can also remind eligible patients during appointments or calls to book within the promotion window and maximize their rewards.
- Do patients earn double points as well? No. This promotion doubles the redemption value of points, not the number of new points earned from treatment.

- Can this offer be redeemed multiple times? No. The offer is valid for a single use per patient during the promotional period.
- Will there be similar offers in the future? ASPIRE regularly provides seasonal and/or product-specific promotions. Encourage patients to keep their contact preferences up to date and subscribe to emails/push notifications to receive future offers.

Patient Eligibility

- Who is eligible for this promotion? Not all patients are eligible. To qualify, patients must meet all the following criteria:
 - Must receive a *Dysport*® treatment between November 10-15, 2025
 - Must redeem ASPIRE points on that same treatment
 - Must not have received a *Dysport*® treatment within the past 90 days
 - Must have existing ASPIRE points available in their account that will not expire before November 15, 2025

Patients who do not meet these criteria (e.g., no points in ASPIRE) will not receive 2X rewards.

*GL-1 and GL-3 evaluated subjects for at least 150 days following treatment. Based on a ≥ 1 -Grade GLSS improvement from baseline utilizing data from 2 double-blinded, randomized, placebo-controlled pivotal studies (GL-1, GL-3) in a post hoc analysis.

†Users=clinical trial subjects. Subject-reported at 12 months (N=120) after 2 treatments 6 months apart in a phase IV, multicenter, prospective study.

‡Based on subject self-assessment. The onset of response at day 1 was 15% (16/105) in GL-1 and 33% (65/200) in GL-3. In the DREAM study, the onset of response at day 1 was 33% (66/200).

Dysport
(abobotulinumtoxinA)

ASPIRE
GALDERMA PRACTICE REWARDS

Please read full Important Safety Information, including Distant Spread of Toxin Effect Boxed Warning, on last page.

Patient Eligibility (continued)

- # TREATMENT USAGE
- Use the drop-down fields and click on a product button to see patients who **have not** received a specific treatment
- In the last 90 days ▾
- ☒ Dysport.
(abobotulinumtoxinA)

Restylane

Restylane
CONTOUR

Restylane
DEFYNE

Restylane
EYELIGHT

Restylane
KYSSE

Restylane
LYFT

Restylane
REFINE

Restylane
SILK


SCULPTRA®

3 **VIEW LIST** **PREVIEW EMAIL**

4		5	
A	B	C	D
Name	Email Address	Phone Number	Active Points
Patient1	patient1@gmail.com	888-888-8888	200
Patient2	patient2@gmail.com	888-888-8888	200
Patient3	patient3@gmail.com	888-888-8888	400

Frequently Asked Questions (continued)

Patient Eligibility (continued)

- Is this promotion available nationwide?
Yes. All ASPIRE-participating practices in the U.S. are eligible to offer this promotion to qualifying patients.
- What if a patient receives Dysport but doesn't redeem their ASPIRE points?
If they do not wish to apply their ASPIRE points to the treatment, they will not receive double rewards. Both the treatment AND point redemption must occur within the promotion window (at the same visit) to qualify.
- What if a patient's points expire before the promotion ends?
Expired points cannot be redeemed. When scheduling patients for this promotion, please encourage them to check their ASPIRE account to ensure the points will not expire before their treatment during the November 10-15 promotion period.
- What if a patient recently received *Dysport* and isn't yet eligible based on the 90-day rule?
Per FDA guidelines, patients who have received *Dysport* in the last 90 days are not eligible to have another *Dysport* treatment entered in ASPIRE.
- What if a patient receives *Dysport* along with Restylane and/or Sculptra during the same visit?
Only the *Dysport* portion of the treatment is eligible for double rewards. Other products will follow standard ASPIRE redemption values.
- Is there a limit to how many patients can participate from one practice?
No. There is no cap per practice—any patient who meets the eligibility criteria can participate.
- Is there a maximum limit on the double rewards?
With ASPIRE, patients can redeem up to a maximum of 1,000 points (\$100), but during the promotion, the points will double to \$200 in total savings. Patients with more than 1,000 points can complete multiple redemptions for additional savings (e.g., redeem 2,000 points [1,000 x 2] for \$400 in total savings).

- If my patient is not a member of ASPIRE, can they sign up and receive double the \$20 Welcome Offer?
No. This offer is for existing ASPIRE members who have existing points to redeem. New members will still receive the standard \$20 Welcome Offer upon enrollment, but it does not qualify for double rewards.

How to Redeem/Enter Treatments

- How do I redeem this offer for my patients?
You simply follow the standard ASPIRE point redemption process:
 1. Redeem the patient's ASPIRE points as usual
 2. The certificate value will automatically reflect double rewards during the promotion period
 3. Apply the certificate at checkout when entering the patient's *Dysport*® treatment

Important reminders:

- Both the ASPIRE points redemption and the treatment entry must occur during the promotion period (November 10-15, 2025)
 - Points redeemed before November 10 will not receive double rewards
 - Treatments entered after November 15 will not receive double rewards
 - Even if the treatment occurred in the promotion window, backdated treatments are not eligible after November 15, so it's very important to enter all eligible treatments during November 10-15
- What if I encounter technical issues during redemption? Who should I contact if I don't see the double value reflected?
If you experience issues redeeming points or entering treatments, please contact ASPIRE Customer Service at 1-844-5-ASPIRE (aspire@galderma.com) immediately before the promotion period ends.

Dysport® ASPIRE Rewards Match Promotion Terms & Conditions

This offer is limited to adult patients who receive a qualifying *Dysport*® treatment in accordance with the product's FDA-approved indication and labeling. You and your healthcare provider must be a member of the ASPIRE Galderma Rewards program ("ASPIRE"). This is a limited quantity offer subject to availability from Galderma and your participating healthcare provider. If you have questions about this offer, please call 1-844-5ASPIRE.

During the time period of November 10-15, 2025 (the "Offer Period"), if you (i) redeem ASPIRE points for an ASPIRE Reward and (ii) use the ASPIRE Reward for a qualifying *Dysport* treatment, Galderma will match the ASPIRE Reward. For example, if you redeem 200 ASPIRE points for a \$20 ASPIRE Reward and use the ASPIRE Reward for a qualifying *Dysport* treatment during the Offer Period, ASPIRE will provide you a \$20 match ASPIRE Reward on the treatment for a total reward of \$40. If you don't use the ASPIRE Reward for a qualifying *Dysport* treatment during the Offer Period, it will retain its normal \$20 value and can later be used for any qualifying Galderma aesthetic treatment. ASPIRE Rewards expire sixty (60) days from the date issued. Galderma employees and their spouses are not eligible for this offer.

This offer is non-transferable. To earn the match, ASPIRE Rewards must be submitted by the treating provider via www.aspirepracticerewards.com during the Offer Period. Galderma will reimburse the provider for the face value of used ASPIRE Rewards, provided that the provider and patient have complied with these terms and conditions. Individual ASPIRE Rewards are valid for one-time use. This offer is limited to one (1) ASPIRE Reward per patient. ASPIRE Rewards cannot be combined with Provider Codes not earned by a healthcare provider under the ASPIRE Galderma Practice Rewards terms and conditions. ASPIRE Rewards have no cash value without simultaneous purchase of a qualifying treatment with a Galderma aesthetic product. This offer is valid only in the U.S. and Puerto Rico (excluding all other U.S. territories), and is void where prohibited, taxed or otherwise restricted by law.

By participating in this offer, you agree to all the terms and conditions of this offer. Galderma reserves the right to cancel or modify this offer without notice. Galderma assumes no responsibility for lost, late, incomplete, or incorrect submissions that fail to be properly entered and submitted to www.aspirepracticerewards.com for any reason. ASPIRE Rewards will be processed and reimbursed in U.S. dollars only.

Dysport®
(abobotulinumtoxinA)

ASPIRE
GALDERMA PRACTICE REWARDS

Please read full Important Safety Information, including Distant Spread of Toxin Effect Boxed Warning, on last page.

Important Safety Information

Indication: *Dysport*® (*abobotulinumtoxinA*) for Injection is an acetylcholine release inhibitor and a neuromuscular blocking agent indicated for the temporary improvement in the appearance of moderate to severe glabellar lines associated with procerus and corrugator muscle activity in adults <65 years of age.

WARNING: DISTANT SPREAD OF TOXIN EFFECTS

Postmarketing reports indicate that the effects of *Dysport* and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These may include asthenia, generalized muscle weakness, diplopia, blurred vision, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence and breathing difficulties. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. The risk of symptoms is probably greatest in children treated for spasticity but symptoms can also occur in adults treated for spasticity and other conditions, particularly in those patients who have underlying conditions that would predispose them to these symptoms. In unapproved uses and in approved indications, cases of spread of effect have been reported at doses comparable to or lower than the maximum recommended total dose.

CONTRAINDICATIONS

- Hypersensitivity to any botulinum toxin product or excipients
- Allergy to cow's milk protein
- Infection at the proposed injection site(s)

WARNINGS AND PRECAUTIONS

- The potency Units of *Dysport* are not interchangeable with other preparations of botulinum toxin products and, therefore, units of biological activity of *Dysport* cannot be compared to or converted into units of any other botulinum toxin products.
- Immediate medical attention may be required in cases of respiratory, speech or swallowing difficulties, or serious hypersensitivity reactions.
- Recommended dose and frequency of administration should not be exceeded.
- Dry eye may occur with glabellar line treatment, if symptoms persist, consider referring patient to an ophthalmologist.
- Concomitant neuromuscular disorder may exacerbate clinical effects of treatment.

ADVERSE REACTIONS

- In clinical studies, the most frequently reported adverse events ($\geq 2\%$) were nasopharyngitis, headache, injection site pain, injection site reaction, upper respiratory tract infection, eyelid edema, eyelid ptosis, sinusitis, nausea, and blood present in urine.

DRUG INTERACTIONS

- Concomitant use of *Dysport* and aminoglycosides or other agents interfering with neuromuscular transmission or muscle relaxants, should be observed closely because effect of *Dysport* may be potentiated.
- Anticholinergic drugs may potentiate systemic anticholinergic effects.
- The effect of administering different botulinum neurotoxins during course of treatment with *Dysport* is unknown.

USE IN SPECIFIC POPULATIONS

- *Dysport* is not recommended for use in children or pregnant women.

You are encouraged to report negative side effects of prescription drugs to the FDA.

Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Please see *Dysport* Full Prescribing Information including Medication Guide at DysportUSA.com.

References

1. *Dysport* prescribing information. Galderma Laboratories, LP; 2023.
2. Rubin MG, Dover J, Glogau RG, Goldberg DJ, Goldman MP, Schlessinger J. The efficacy and safety of a new U.S. Botulinum toxin type A in the retreatment of glabellar lines following open-label treatment. *J Drugs Dermatol*. 2009;8(5):439-444.
3. Monheit GD, Baumann L, Maas C, Rand R, Down R. Efficacy, safety, and subject satisfaction after abobotulinumtoxinA treatment for moderate to severe glabellar lines. *Dermatol Surg*. 2020;46(1):61-69.
4. Brandt F, Swanson N, Baumann L, Huber B. Randomized, placebo-controlled study of a new botulinum toxin type A for treatment of glabellar lines: efficacy and safety. *Dermatol Surg*. 2009;35(12):1893-1901.
5. Data on file. MA-35497. Post hoc analysis. Fort Worth, TX: Galderma Laboratories, L.P., 2017.
6. Schlessinger J, Cohen JL, Shamban A, et al. A multicenter study to evaluate subject satisfaction with two treatments of AbobotulinumtoxinA a year in the glabellar lines. *Dermatol Surg*. 2021;47(4):504-509.

© 2025 Galderma Laboratories, L.P. The *Dysport* trademark is used under license.
All trademarks are the property of their respective owners. US-DYS-2500156

Dysport
(abobotulinumtoxinA)

ASPIRE
GALDERMA PRACTICE REWARDS

GALDERMA
EST. 1981